The diagnosis and treatment of hematologic cancers is rapidly evolving, driven by advancements in technology, understanding of the molecular basis for disease, and new therapy options. Increasingly, next generation sequencing (NGS) is being utilized for diagnostic workup, prognostic assessment, and therapy selection. Myeloid neoplasms represent a complex and heterogeneous group of diseases which may display overlapping clinical, morphologic, and genomic features. In this workshop, we will highlight the utility for myeloid comprehensive genomic profiling (CGP) across a broad spectrum of categories, including acute myeloid leukemia (AML), where rapid genomic testing may also lead to improved patient outcomes.
